Positive News SentimentPositive NewsNASDAQ:NRXP NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis $2.99 -0.04 (-1.32%) Closing price 04:00 PM EasternExtended Trading$3.03 +0.04 (+1.34%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About NRx Pharmaceuticals Stock (NASDAQ:NRXP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NRx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.92▼$3.0950-Day Range$2.99▼$4.4852-Week Range$1.62▼$5.05Volume766,587 shsAverage Volume587,297 shsMarket Capitalization$129.47 millionP/E RatioN/ADividend YieldN/APrice Target$34.50Consensus RatingHold Company Overview NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly conditions involving mood disorders, suicidality and post-traumatic stress disorder. The company’s programs are designed to address significant unmet medical needs in psychiatric and neurological care. NRx Pharmaceuticals’ lead investigational product is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for bipolar depression with acute suicidal ideation or behavior. The company has also evaluated NRX-100, an intravenous ketamine formulation, as part of its efforts to develop treatments for suicidal depression. These products remain investigational and require regulatory approval before they can be marketed for their intended uses. The company was formed from NeuroRx, Inc. and became publicly traded following a business combination with Big Rock Partners Acquisition Corp. in 2021. NRx Pharmaceuticals conducts research and clinical-development activities in the United States and has pursued regulatory and development programs intended for broader international markets. Jonathan Javitt, M.D., M.P.H., is the company’s founder and chief executive officer.AI Generated. May Contain Errors. Read More NRx Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreNRXP MarketRank™: NRx Pharmaceuticals scored higher than 40% of companies evaluated by MarketBeat, and ranked 683rd out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingNRx Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialNRx Pharmaceuticals has a consensus price target of $34.50, representing about 1,053.8% upside from its current price of $2.99.Amount of Analyst CoverageNRx Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about NRx Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of NRx Pharmaceuticals is -5.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NRx Pharmaceuticals is -5.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about NRx Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.12% of the float of NRx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverNRx Pharmaceuticals has a short interest ratio ("days to cover") of 16.27, which indicates bearish sentiment.Change versus previous monthShort interest in NRx Pharmaceuticals has recently increased by 5.14%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNRx Pharmaceuticals does not currently pay a dividend.Dividend GrowthNRx Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment1.79 News SentimentNRx Pharmaceuticals has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for NRx Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for NRXP on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added NRx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NRx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders6.40% of the stock of NRx Pharmaceuticals is held by insiders.Percentage Held by Institutions4.27% of the stock of NRx Pharmaceuticals is held by institutions.Read more about NRx Pharmaceuticals' insider trading history. Receive NRXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NRXP Stock News HeadlinesAnalyzing LENZ Therapeutics (NASDAQ:LENZ) & NRx Pharmaceuticals (NASDAQ:NRXP)September 25 at 4:44 AM | americanbankingnews.comNRx Pharmaceuticals Reports FDA Reclassifies Ketamine Amendment As MinorSeptember 16, 2026 | rttnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 25 at 1:00 AM | Chaikin Analytics (Ad)NRx Pharmaceuticals (NASDAQ:NRXP) Earns Buy Rating from BTIG ResearchSeptember 16, 2026 | americanbankingnews.comNRx Pharmaceuticals Announces FDA Reclassification of ANDA Amendment for Preservative-Free Ketamine, Revises GDUFA Goal Date to November 10, 2026September 15, 2026 | quiverquant.comQNRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free KetamineSeptember 15, 2026 | globenewswire.comGeNeuro Secures European Patent For GNK-301 In ALSSeptember 14, 2026 | rttnews.comNRx Pharmaceuticals: Promising Ketamine Opportunity In PsychiatrySeptember 14, 2026 | seekingalpha.comSee More Headlines NRXP Stock Analysis - Frequently Asked Questions How have NRXP shares performed this year? NRx Pharmaceuticals' stock was trading at $2.71 at the beginning of 2026. Since then, NRXP stock has increased by 10.3% and is now trading at $2.99. How were NRx Pharmaceuticals' earnings last quarter? NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) released its earnings results on Friday, August, 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.33. The company earned $1.10 million during the quarter, compared to analyst estimates of $1.33 million. Read the conference call transcript. When did NRx Pharmaceuticals' stock split? NRx Pharmaceuticals shares reverse split before market open on Tuesday, April 2nd 2024.The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are NRx Pharmaceuticals' major shareholders? Top institutional shareholders of NRx Pharmaceuticals include Squarepoint Ops LLC (0.03%). View institutional ownership trends. How do I buy shares of NRx Pharmaceuticals? Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NRx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that NRx Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), Meta Platforms (META), GE Aerospace (GE) and Disc Medicine (IRON). Company Calendar Last Earnings8/14/2026Today9/25/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 NRXP's financial health is in the Green zone, according to TradeSmith. NRXP has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NRXP CIK1719406 Webnrxpharma.com Phone(484) 254-6134FaxN/AEmployees29Year Founded2015Price Target and Rating Average Price Target for NRx Pharmaceuticals$34.50 High Price Target$49.00 Low Price Target$10.00 Potential Upside/Downside+1,053.8%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$28.62 million Net Margins-691.81% Pretax Margin-692.13% Return on EquityN/A Return on Assets-63.92% Debt Debt-to-Equity RatioN/A Current Ratio0.86 Quick Ratio0.86 Sales & Book Value Annual Sales$1.23 million Price / Sales105.26 Cash FlowN/A Price / Cash FlowN/A Book Value($0.54) per share Price / Book-5.54Miscellaneous Outstanding Shares43,300,000Free Float40,525,000Market Cap$129.47 million OptionableOptionable Beta2.19 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:NRXP) was last updated on 9/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NRx Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
